Next Article in Journal
Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine
Next Article in Special Issue
The Potential of Soluble Human Leukocyte Antigen Molecules for Early Cancer Detection and Therapeutic Vaccine Design
Previous Article in Journal
Post-Vaccination Yellow Fever Antiserum Reduces Zika Virus in Embryoid Bodies When Placental Cells are Present
Previous Article in Special Issue
Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy
Review

Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma

1
Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
2
Pediatric Translational Research Unit, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
3
Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
4
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, Thailand
*
Authors to whom correspondence should be addressed.
Shared equal contribution.
Vaccines 2020, 8(4), 753; https://doi.org/10.3390/vaccines8040753
Received: 29 October 2020 / Revised: 4 December 2020 / Accepted: 10 December 2020 / Published: 11 December 2020
(This article belongs to the Special Issue Cancer Immunotherapy: Advances and Future Prospects)
Chimeric antigen receptors (CARs) are among the curative immunotherapeutic approaches that exploit the antigen specificity and cytotoxicity function of potent immune cells against cancers. Neuroblastomas, the most common extracranial pediatric solid tumors with diverse characteristics, could be a promising candidate for using CAR therapies. Several methods harness CAR-modified cells in neuroblastoma to increase therapeutic efficiency, although the assessment has been less successful. Regarding the improvement of CARs, various trials have been launched to overcome insufficient capacity. However, the reasons behind the inadequate response against neuroblastoma of CAR-modified cells are still not well understood. It is essential to update the present state of comprehension of CARs to improve the efficiency of CAR therapies. This review summarizes the crucial features of CARs and their design for neuroblastoma, discusses challenges that impact the outcomes of the immunotherapeutic competence, and focuses on devising strategies currently being investigated to improve the efficacy of CARs for neuroblastoma immunotherapy. View Full-Text
Keywords: CAR T cells; immunotherapy; pediatric neuroblastoma; strategy CAR T cells; immunotherapy; pediatric neuroblastoma; strategy
Show Figures

Figure 1

MDPI and ACS Style

Sawaisorn, P.; Atjanasuppat, K.; Anurathapan, U.; Chutipongtanate, S.; Hongeng, S. Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma. Vaccines 2020, 8, 753. https://doi.org/10.3390/vaccines8040753

AMA Style

Sawaisorn P, Atjanasuppat K, Anurathapan U, Chutipongtanate S, Hongeng S. Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma. Vaccines. 2020; 8(4):753. https://doi.org/10.3390/vaccines8040753

Chicago/Turabian Style

Sawaisorn, Piamsiri, Korakot Atjanasuppat, Usanarat Anurathapan, Somchai Chutipongtanate, and Suradej Hongeng. 2020. "Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma" Vaccines 8, no. 4: 753. https://doi.org/10.3390/vaccines8040753

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop